Professor Manuel Guzman is Professor of Molecular Biology at the Complutense University in Madrid where he has been a leading light in discovering the anticancer properties of cannabinoids such as THC and CBD. He led the team behind the first ever clinical trial for THC as an antitumoral agent in the rare type of brain cancer, glioblastoma.
I recorded this interview for an article for Project CBD examining just how close we are to the approval of a cannabis-based anticancer drug, but managed to draw Manuel into a whole host of fascinating topics, on which he talked openly and frankly.
Highlights include:
A summary of how near or far we are away from a cannabis-based cancer drug.
How the bar is set higher for cannabinoids compared to other areas of research.
What other types of cancer are likely to move onto the clinical studies stage in cannabinoid research.
Manuel's view on GW Pharma's 'mining' of the cannabis field with patents for different types of cannabinoid combinations and diseases.
Why a cannabis-based cancer drug will always be trialled alongside standard treatments such as chemo or radiotherapy.
Practical advice from Manuel for patients with cancer about how to safely use cannabis oil.
The biphasic effect of THC and how this may influence its antitumoral activity.
An explanation of the difference between tolerability and tolerance.
A call to action to patients to play their part in the normalisation of cannabis by telling their doctors about their cannabis use.
Transcript:
For space reasons, I cannot include the full transcript here, but feel free to contact me via my website marybiles.com and I will happily send it.